Eaton Vance Management Cut Its Celgene (CELG) Stake; AKER SOLUTIONS HOLDING ASA ORDINARY SHAR (AKRTF) Sellers Increased By 1.78% Their Shorts

June 24, 2018 - By Peter Erickson

Celgene Corporation (NASDAQ:CELG) Logo

AKER SOLUTIONS HOLDING ASA ORDINARY SHAR (OTCMKTS:AKRTF) had an increase of 1.78% in short interest. AKRTF’s SI was 1.41 million shares in June as released by FINRA. Its up 1.78% from 1.38 million shares previously. With 100 avg volume, 14086 days are for AKER SOLUTIONS HOLDING ASA ORDINARY SHAR (OTCMKTS:AKRTF)’s short sellers to cover AKRTF’s short positions. The SI to AKER SOLUTIONS HOLDING ASA ORDINARY SHAR’s float is 0.97%. It closed at $6 lastly. It is down 0.00% since June 24, 2017 and is . It has underperformed by 12.57% the S&P500.

Eaton Vance Management decreased Celgene Corp (CELG) stake by 17.56% reported in 2018Q1 SEC filing. Eaton Vance Management sold 585,679 shares as Celgene Corp (CELG)’s stock declined 18.51%. The Eaton Vance Management holds 2.75 million shares with $245.35 million value, down from 3.34 million last quarter. Celgene Corp now has $57.12B valuation. The stock decreased 0.43% or $0.34 during the last trading session, reaching $78.8. About 5.01M shares traded. Celgene Corporation (NASDAQ:CELG) has declined 32.65% since June 24, 2017 and is downtrending. It has underperformed by 45.22% the S&P500. Some Historical CELG News: 06/04/2018 – Incyte’s new immunotherapy drug epacadostat failed to work in conjunction with Merck’s blockbuster melanoma drug Keytruda; 08/05/2018 – X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combination of X4P-001-IO and Opdivo® (nivolumab); 10/04/2018 – TUBEROUS SCLEROSIS ALLIANCE SALUTES FDA APPROVAL OF AFINITOR® DISPERZ (EVEROLIMUS) AS THE FIRST ADJUNCTIVE TREATMENT APPROVED IN US FOR PATIENTS AGED 2 YEARS AND OLDER WITH TUBEROUS SCLEROSIS COMPLE…; 28/03/2018 – bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in; 16/05/2018 – Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions; 14/05/2018 – Celgene at American Society of Clinical Oncology Meeting Jun 3; 29/05/2018 – Evotec: Celgene Decided to Expand Collaboration to Include Additional Cell Lines; 05/04/2018 – Celgene Corporation | pomalidomide | Pomalyst® | 04/04/2018 | Treatment of Kaposi sarcoma | Designated | NFDA | N/A | | N/A; 30/05/2018 – DENALI THERAPEUTICS INC – DENALI MAY MAKE FUTURE CONTINGENT PAYMENTS UP TO MAXIMUM OF $447 MLN UPON ACHIEVEMENT OF MILESTONES; 06/03/2018 – Celgene Completes Acquisition Of Juno Therapeutics, Inc., Advancing Global Leadership In Cellular Immunotherapy

Analysts await Celgene Corporation (NASDAQ:CELG) to report earnings on July, 26. They expect $1.87 EPS, up 11.31% or $0.19 from last year’s $1.68 per share. CELG’s profit will be $1.36 billion for 10.53 P/E if the $1.87 EPS becomes a reality. After $1.61 actual EPS reported by Celgene Corporation for the previous quarter, Wall Street now forecasts 16.15% EPS growth.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “Long-Term Investors Take Note — These 5 Big Pharma Companies Have the Best Pipelines” on June 24, 2018, also Nasdaq.com with their article: “2 Incredibly Cheap Value Stocks to Buy Now” published on June 22, 2018, Seekingalpha.com published: “5 Reasons Why Celgene Will Recover” on June 01, 2018. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Seekingalpha.com and their article: “Finger-Pointing At Celgene” published on June 14, 2018 as well as Nasdaq.com‘s news article titled: “Why I’m Bullish on the Riskiest Big Biotech Stock on the Market” with publication date: June 21, 2018.

Among 35 analysts covering Celgene Corporation (NASDAQ:CELG), 21 have Buy rating, 1 Sell and 13 Hold. Therefore 60% are positive. Celgene Corporation had 151 analyst reports since July 21, 2015 according to SRatingsIntel. The company was downgraded on Thursday, October 5 by Morgan Stanley. As per Thursday, January 25, the company rating was maintained by SunTrust. On Friday, October 27 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The stock has “Outperform” rating by BMO Capital Markets on Friday, July 28. The company was maintained on Monday, October 30 by Credit Suisse. Credit Suisse maintained Celgene Corporation (NASDAQ:CELG) on Tuesday, April 19 with “Outperform” rating. The firm has “Outperform” rating by RBC Capital Markets given on Friday, January 29. Canaccord Genuity maintained Celgene Corporation (NASDAQ:CELG) rating on Monday, October 16. Canaccord Genuity has “Buy” rating and $156.0 target. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by RBC Capital Markets on Wednesday, April 4. The company was initiated on Tuesday, September 1 by Raymond James.

Since February 8, 2018, it had 2 insider buys, and 5 selling transactions for $5.91 million activity. LOUGHLIN JAMES J had sold 17,750 shares worth $1.40 million on Monday, June 4. Shares for $299,594 were bought by Alles Mark J on Thursday, February 8. KAPLAN GILLA sold $1.77M worth of stock or 18,500 shares. MARIO ERNEST sold 13,370 shares worth $1.26M. 13,000 shares were sold by CASEY MICHAEL D, worth $1.02 million on Thursday, June 7.

Investors sentiment decreased to 0.79 in Q1 2018. Its down 0.04, from 0.83 in 2017Q4. It worsened, as 120 investors sold CELG shares while 470 reduced holdings. 106 funds opened positions while 363 raised stakes. 513.18 million shares or 8.59% less from 561.38 million shares in 2017Q4 were reported. Fiduciary Trust has 26,436 shares for 0.07% of their portfolio. Natixis Advisors Limited Partnership holds 0.13% in Celgene Corporation (NASDAQ:CELG) or 143,035 shares. Calamos Wealth Management Limited Liability Company invested 0.08% in Celgene Corporation (NASDAQ:CELG). Prtn Ltd holds 29,045 shares. Stanley has invested 0.19% in Celgene Corporation (NASDAQ:CELG). Adell Harriman & Carpenter Inc accumulated 20,500 shares. Old Natl Fincl Bank In holds 59,556 shares. Valley Natl Advisers has invested 0.27% in Celgene Corporation (NASDAQ:CELG). Proshare Advsr Limited Co stated it has 0.51% of its portfolio in Celgene Corporation (NASDAQ:CELG). Cadence Management Lc holds 0.12% or 20,071 shares. Tci Wealth Advsrs reported 2,007 shares. Hugh Johnson Advsr Ltd Liability has 21,365 shares for 0.57% of their portfolio. City owns 2,238 shares. New England & Management Incorporated holds 1.06% or 17,776 shares in its portfolio. Blair William & Co Il reported 726,155 shares.

Eaton Vance Management increased Altaba Inc stake by 27,152 shares to 194,056 valued at $14.37M in 2018Q1. It also upped Newmarket Corp (NYSE:NEU) stake by 12,375 shares and now owns 36,165 shares. Universal Display Corp (NASDAQ:OLED) was raised too.

Aker Solutions ASA provides products, systems, and services to the gas and oil industry worldwide. The company has market cap of $. It operates through two divisions, Subsea and Field Design. It has a 50.85 P/E ratio. It offers services ranging from concept screening and design through manufacturing, installation, and commissioning to operational support and maintenance services.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts